The EPA should set up formal working relationships with other federal organizations in order to improve research about pharmaceuticals and other contaminants in drinking water, according to a US Government Accountability Office (GAO) study published September 8. Although the amounts of pharmaceuticals found in public drinking water systems have been low, generally detected in parts […]
The US Congress will likely approve a new deal for the inspection of overseas drug manufacturing plants, many of which are not routinely FDA inspected. The generic drug industry’s reluctance to pay inspection fees has changed, partly due to the Heparin scandal and the hesitancy of Congress to designate money for inspections. Mylan President Heather […]
Waltham, MA 9/8/11—PerkinElmer has agreed to acquire Caliper Life Sciences for $10.50 per share, a 42% premium over the closing price on September 7, for a total net purchase price of $600 million in cash. Caliper Life Sciences is a provider of microfluidic, molecular imaging and sample preparation technologies. “The acquisition of Caliper Life Sciences […]
President Obama and Congress have reached a compromise on the US debt in the hope of digging the US out of its $1.5 trillion annual deficit, though its impact on science is not yet clear. The Budget Control Act of 2011 was signed into law on August 2. It contains about $917 billion in spending […]
The outlook for the global solar industry has dimmed from last year. The industry is projected to grow relatively little this year. The slump is due to lower government subsidies and excessive capacity expansion over the past six months. Spot market prices of solar cells and wafers have declined 40% since January and in many […]
“Power and Promise: Agbioscience in the North Central United States,” a Battelle study released earlier this month, shows that the region is a leader in the $125 billion US agricultural industry in terms of production and R&D. The region, made up of 12 states, accounts for just 21% of the US geographically but produces 45% […]
A global survey of 282 senior executives at pharmaceutical, biotech, medical device and service firms found dissatisfaction with their companies’ level of innovation. Their companies’ R&D strategy was rated “moderately effective” by 49% of respondents. Cost was ranked by 47% as their firms’ biggest challenge (respondents ranked their top three challenges) to improving innovation, followed […]
This month, the US Court of Appeals for the Federal Circuit ruled in favor of gene patents. The Myriad Genetics case involved the firm’s patents on the BRCA1 and BRCA 2 genes for predicting the risk of breast and ovarian cancer. The court ruled that the chemical structure of the isolated DNA covered by the […]
In 2010, the aggregate profit margin for the firms in Chemical & Engineering News’ survey of the top 50 chemical companies was 11.4%, the highest profit margin in 15 years. Sales at the 49 firms showing similar year-over-year figures grew 25.3% to $857 billion in 2010. Operating profits for the 47 firms with similar year-over-year […]
Thanks to the new ASTM annex, D7566-11, the 2% of global carbon dioxide emissions that is contributed by passenger jets will be reduced. Standards for testing the “second generation” of biofuels, derived from inedible plants, tallows (animal fats) and organic waste, have been approved to power commercial planes. ASTM has approved testing standards for a […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.

